摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3-甲氧基丙基)-2-吡咯烷酮 | 157769-80-7

中文名称
N-(3-甲氧基丙基)-2-吡咯烷酮
中文别名
N-甲氧基丙基-2-吡咯烷酮;1-(3-甲氧基丙基)-2-吡咯烷酮
英文名称
1-(3-Methoxypropyl)pyrrolidin-2-one
英文别名
——
N-(3-甲氧基丙基)-2-吡咯烷酮化学式
CAS
157769-80-7
化学式
C8H15NO2
mdl
——
分子量
157.21
InChiKey
OIKFIOGYFGWPAB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    281℃
  • 密度:
    1.026
  • 闪点:
    124℃

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    11
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • NOVEL COMPOUNDS
    申请人:GRAUERT Matthias
    公开号:US20130184248A1
    公开(公告)日:2013-07-18
    This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.
    这项发明涉及到式I的化合物,它们作为mGlu5受体活性的正向变构调节剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神疾病,如精神分裂症或认知功能下降,如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
  • [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES SUBSTITUÉS ANTIDIABÉTIQUES
    申请人:MERCK SHARP & DOHME
    公开号:WO2015089809A1
    公开(公告)日:2015-06-25
    The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    本发明涉及一种由公式I表示的化合物:以及它们的药用可接受盐。公式I的化合物是G蛋白偶联受体40(GPR40)的激动剂,可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病,以及通常与该疾病相关的状况,包括肥胖和脂质紊乱,如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。
  • [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
    申请人:MERCK SHARP & DOHME
    公开号:WO2015095256A1
    公开(公告)日:2015-06-25
    The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    本发明涉及一种由公式(I)表示的化合物:以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40(GPR40)的激动剂,并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病,以及通常与该疾病相关的状况,包括肥胖和脂质紊乱,如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
  • [EN] NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
    申请人:DAEGU GYEONGBUK MEDICAL INNOVATION FOUND
    公开号:WO2021145729A1
    公开(公告)日:2021-07-22
    The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.
    本发明涉及一种制备具有选择性功能化酪氨酸的生物材料的方法,具有选择性功能化酪氨酸的生物材料,以及含有该生物材料作为活性成分的药物组合物。本发明的一种制备生物材料的方法,其中将由式2表示的化合物偶联到生物材料,使得该化合物能够选择性地偶联到酪氨酸,且在生物材料中的产率较高,酪氨酸位于水溶液表面,使得其与酪氨酸以外的氨基酸不发生偶联,当只有一个酪氨酸存在时,不会出现异质混合物,同时保持生物材料的固有活性,因此该化合物可以有效地用作含有生物材料药物的药物组合物的活性成分。此外,该方法可以选择性功能化酪氨酸,因此可以有效地用于生物材料中的酪氨酸功能化。
  • RESIN COMPOSITION
    申请人:TORAY INDUSTRIES, INC.
    公开号:US20190241716A1
    公开(公告)日:2019-08-08
    The present invention provides a resin composition having a high sensitivity and serving to produce a cured film with a low water absorption rate. The resin composition includes: (a) an alkali-soluble resin and (b1) an amido-phenol compound containing a phenolic hydroxyl group in which a monovalent group as represented by the undermentioned general formula (1) is located at the ortho position and/or (b2) an aromatic amido acid compound containing a carboxy group in which a monovalent group as represented by the undermentioned general formula (2) is located at the ortho position: wherein in general formula (1), X is a monovalent organic group having an alkyl group that contains 2 to 20 carbon atoms and bonds directly to the carbonyl carbon in general formula (1) or a monovalent organic group that has —(YO) n —; and in general formula (2), U is a monovalent organic group that has an alkyl group containing 2 to 20 carbon atoms and bonding directly to the amide nitrogen in general formula (2) or a monovalent organic group that has —(YO) n —; wherein Y is an alkylene group containing 1 to 10 carbon atoms and n is an integer of 1 to 20.
    本发明提供了一种树脂组合物,具有高灵敏度,并用于生产具有低吸水率的固化膜。该树脂组合物包括:(a)可溶于碱的树脂和(b1)含有酚羟基的酰胺酚化合物,其中酚羟基化合物中的单价基在邻位上,和/或(b2)含有羧基的芳香酰胺酸化合物,其中羧基化合物中的单价基在邻位上,其通式如下所示:在通式(1)中,X是一个单价有机基,具有含有2到20个碳原子的烷基,并直接连接到通式(1)中的羰基碳,或具有—(YO)n—的单价有机基;在通式(2)中,U是一个单价有机基,具有含有2到20个碳原子的烷基,并直接连接到通式(2)中的酰胺氮,或具有—(YO)n—的单价有机基;其中Y是含有1到10个碳原子的烷基,n是1到20的整数。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦